-
Cystic Fibrosis: Causes, Inheritance, Treatment and Diagnosis(Post)
What is Cystic Fibrosis? Cystic fibrosis (CF) is a genetic disorder that impairs the body's ability to produce sweat and thick mucus. CF causes mucus to build up in t
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
IgA Test – Normal Ranges, Results & What They Mean(Post)Clinical · Immunology Guide IgA Test: Normal Ranges, Results & What They Mean [2026] What the immunoglobulin A blood test measures, how result
Ordering FAQs(Page) Mouse Monoclonal Antibody(Post)Mouse monoclonal antibodies are a valuable tool in the biomedical field. They can be used for a variety of applications, from research to clinical diagnostics. In this blog post, we will di
Urea Assays(Page)Urea Assay Kits | Urea Cycle, Ammonia & Amino Acid Assays | Assay Genie
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Treponema pallidum Antibodies: Comprehensive Guide to Diagnostic and Clinical Relevance(Post)Treponema pallidum, the causative agent of syphilis, triggers an immune response that produces antibodies detectable by laboratory tests. Diagnosing syphilis often involves detecting thes
CV en ELISA : 5 vérifications pour techniciens si le %CV > 10 %(Post)CV en ELISA : 5 vérifications pour techniciens si le %CV > 10 % Le %CV en ELISA se calcule ainsi : (écart-type ÷ moyenne) × 100. Visez un CV intra-plaque inférieur à 10 % (idéalement sous 8 %) et un
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Questions About Dilutions? A Real Example of How to Prepare Your ELISA Solutions(Post)Quick answer A researcher preparing a Human IL-18 ELISA wasn't sure whether the protocol's “300-fold” HRP-Streptavidin step meant adding 40 µL of concentrat
Programmable Synthetic Hybrid Receptors (Hybrid-Rs): The Next Generation of Precision Immunotherapy(Post)Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th
RIPA Buffer Recipe(Page) Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
PD-L1 in Cancer Immunotherapy: Key Insights(Post)PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect